Evolving Regulatory Landscape for Model Informed Drug Development (MIDD): Impact of the Draft ICH M15 Guidance On-Demand Webinar 模型引导的药物开发(MIDD)的监管环境演变:ICH M15 指南草案的影响 SVP, PBPK Consultancy Services, Certara SVP, Quantitative Science Services, Certara Sr. Director, Clinical Pharmacology, Certara…Certara2025 年 5 月 23 日
CERTAINTY 2025: The power of Model-Informed Drug Development Blog CERTAINTY 2025: 模型引导的药物开发的强大力量 We cover the key takeaways from CERTAINTY 2025, including the power of Model-Informed Drug Development…Certara2025 年 5 月 16 日
Explore First: How a Stepwise Approach to QTc Studies Reduces Time, Cost, and Regulatory Risk Webinar 探索先行:分阶段 QTc 研究策略如何减少时间、成本及监管风险 Certara2025 年 5 月 5 日
Non-Animal Navigator™: Expert strategy and AI-enabled biosimulation to reduce, refine, or replace animal studies Fact Sheet Non-Animal Navigator™: 专家策略与 AI 生物模拟减少、优化或替代动物实验 Certara Non-Animal Navigator™ 解决方案通过以下方式助力企业转型:Certara2025 年 4 月 30 日
Certara Announces Second Annual Certainty U.S. Event Announcement Certara 举办 Second Annual Certainty U.S. 活动 Certara’s premier client conference explores how in-silico methods and biosimulation at scale derisk every stage…Certara2025 年 4 月 22 日
In case you missed it: CHI + Certara Webinar on Artificial Intelligence (AI) -Powered Model-Informed Drug Development (MIDD) Blog 不容错过:CHI 与 Certara 关于人工智能(AI)赋能模型引导的药物开发(MIDD)网络研讨会 2025 年 4 月 18 日 What’s next for drug development? Recapping our MIDD in the age of…Certara2025 年 4 月 18 日
Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing Press Release Certara 推出 Non-Animal Navigator™ 解决方案,助力药物开发者减少对动物试验的依赖 New offering provides strategic guidance and AI-enabled biosimulation to navigate FDA’s Roadmap to Reducing Animal…Certara2025 年 4 月 14 日
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study Publication HIV 病毒学抑制青少年中长效注射用 cabotegravir 与长效注射用 rilpivirine 联合用药的安全性研究(IMPAACT 2017/MOCHA):一项 1/2 期、多中心、开放标签、非比较性的剂量探索研究 The IMPAACT 2017/MOCHA study, a phase 1/2 multicenter trial across five countries, assessed the safety,…Certara2025 年 3 月 20 日
How biosimulation and virtual trials can bust through clinical trial roadblocks Press Coverage How biosimulation and virtual trials can bust through clinical trial roadblocks Discover how using biosimulation for rare disease drug development can help overcome statistical and recruitment…Certara2025 年 3 月 14 日
MIDD in Japan – Implementations, challenges and opportunities Publication MIDD in Japan – Implementations, challenges and opportunities In Japan, there has been a growing adoption of Model Informed Drug Development (MIDD) approaches…Certara2025 年 3 月 12 日